---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093976"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:06:38.444875+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sana Q2 net loss $50.3M ($0.21/sh); cash $251.6M; operating burn target <$200M

## Summary
- Net loss $50.3M ($0.21 per share), improved from $114M loss ($0.59) in Q2 2023.
- Cash and equivalents $251.6M; expects 2024 operating cash burn below $200M.
- Four clinical trials ongoing across seven indications; initial data expected in 2024 for SC291, SC262, and UP421.
- R&D expenses decreased to $60.9M (Q2 2024) from $73.0M (Q2 2023) due to strategic repositioning.
- Non-GAAP operating cash burn for H1 2024 was $104.6M vs $136.5M in H1 2023.

## SEC filing metadata
- accession: 0000950170-24-093976
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017024093976/0000950170-24-093976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017024093976/sana-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093976
- JSON: https://secwatch.observer/filing/0000950170-24-093976.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093976.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.